
Models & ResearchSuperhuman – Zain Kahn · 44m ago
Experimental pill halts pancreatic tumor growth in early clinical study
An early stage trial evaluating the compound Daraxonrasib showed tumor progression stopped in nine out of ten pancreatic cancer patients. More than sixty percent of participants experienced tumor shrinkage, outperforming historical outcomes from standard chemotherapy. Researchers view the data as an encouraging step toward treating an illness with notoriously poor survival rates.
Read the original